8-K/A: SeaStar Medical Advances Trials, Boosts Cash

SeaStar Medical reports progress in its NEUTRALIZE-AKI trial, positive QUELIMMUNE survival data, and a significant capital raise, extending its financial runway into 2026.

Summary

• SeaStar Medical enrolled 31 new patients in its adult NEUTRALIZE-AKI trial, reaching 125 of 200 anticipated patients, triggering an interim analysis for the first 100 patients.
• The company secured three new top-rated children's hospitals as customers for its QUELIMMUNE therapy.
• Positive survival results were reported from the SAVE Surveillance Registry for the first 20 pediatric patients treated with QUELIMMUNE, showing 75% survival through 28 days with no device-related safety events.
• The U.S. Centers for Medicare & Medicaid Services (CMS) agreed to cover certain expenses for patients in the NEUTRALIZE-CRS investigational clinical trial.
• A $2 million United States Department of Defense (DoD) grant was awarded to The Autonomous Reanimation and Evacuation (AREVA) Research Institute to study SeaStar Medical's SCD therapy for warfighters with severe burns, inhalation injury, and infection.
• Net revenue for the three months ended June 30, 2025, was approximately $0.3 million, reflecting initial sales of the QUELIMMUNE pediatric SCD therapy.
• Research and development expenses decreased to $1.0 million in Q2 2025 from $2.3 million in Q2 2024.
• General and administrative expenses decreased to $1.0 million in Q2 2025 from $2.3 million in Q2 2024.
• Net loss for Q2 2025 improved to approximately $2.0 million, or $0.18 per share, compared to a net loss of $3.2 million, or $1.03 per share, in Q2 2024.
• Cash at June 30, 2025, was $6.3 million, up from $1.8 million at December 31, 2024.
• The company raised $12.4 million in gross proceeds through public and registered direct offerings in June, July, and August 2025, extending its financial runway into 2026.

Sentiment

Score: 7

Explanation: The sentiment is positive due to significant clinical trial progress, encouraging commercial adoption and survival data for QUELIMMUNE, and a successful capital raise that extends the financial runway. While the company remains unprofitable and experienced share dilution, the operational advancements and improved cash position outweigh the immediate financial negatives, indicating strong progress towards key milestones.

Positives

• Significant progress in NEUTRALIZE-AKI trial enrollment, reaching over 60% of target patients and triggering interim analysis.
• Positive survival data from the QUELIMMUNE SAVE Surveillance Registry, showing 75% survival in critically ill pediatric patients, potentially exceeding a 50% reduction in loss of life compared to historical data.
• Expansion of QUELIMMUNE customer base with three new top-rated children's hospitals adopting the therapy.
• Receipt of a rare CMS agreement to cover expenses for patients in the NEUTRALIZE-CRS trial, indicating regulatory recognition and potential for future reimbursement.
• Award of a $2 million DoD grant to explore SCD therapy for warfighters, validating the technology's potential beyond current indications and providing non-dilutive funding for research.
• Implementation of cost-saving measures, leading to a reduction in R&D and G&A expenses.
• Improved net loss in Q2 2025 ($2.0 million) compared to Q2 2024 ($3.2 million).
• Successful capital raise of $12.4 million, significantly increasing cash reserves and extending the company's financial runway into 2026.

Negatives

• Other expenses (net) increased by approximately $1.7 million in Q2 2025, primarily due to a decline in favorable gains from the change in fair value of liability classified warrants and a one-time financing fee.
• Despite improved net loss, the company continues to operate at a net loss of $2.0 million for the quarter.
• Significant dilution occurred, with weighted-average shares outstanding increasing from 3.2 million in Q2 2024 to 11.3 million in Q2 2025 due to capital raises.

Risks

• May not obtain regulatory approval for SCD product candidates.
• May not be able to raise sufficient capital to fund operations, including current or future clinical trials.
• Unable to successfully develop and commercialize products or services, or experience significant delays in doing so, including failure to achieve approval of products by applicable federal and state regulators.
• May never achieve or sustain profitability.
• Unable to secure additional financing on acceptable terms.
• Third-party suppliers and manufacturers may not be able to fully and timely meet their obligations.
• Risk of product liability or regulatory lawsuits or proceedings relating to products and services.
• Unable to secure or protect intellectual property.

Future Outlook

The company anticipates interim results for the first 100 patients in the NEUTRALIZE-AKI trial in the third quarter of 2025, along with the presentation of additional data from the SAVE Surveillance Registry and onboarding of more children's hospitals. Assuming a successful outcome from the NEUTRALIZE-AKI trial, a Pre-Marketing Approval (PMA) application for the Selective Cytopheretic Device (SCD) therapy for adult patients with Acute Kidney Injury (AKI) requiring continuous renal replacement therapy (CRRT) is planned for 2026.

Management Comments

• "Since the beginning of the second quarter, we have made great progress on several fronts. We enrolled 31 additional patients in the NEUTRALIZE-AKI trial, reported three new QUELIMMUNE customers from top-rated U.S.-based children’s hospitals, announced positive survival results for the first 20 pediatric patients treated in a commercial setting with QUELIMMUNE from the SAVE Surveillance Registry, and raised additional capital to shore up our balance sheet."
• "We are now focused on several important upcoming, value-creating milestones. These include the interim results for the first 100 patients in the NEUTRALIZE-AKI trial, presentation of additional data from the SAVE Surveillance Registry, and the onboarding of other notable children’s hospitals to our customer list."
• "Also, assuming a successful outcome from our NEUTRALIZE-AKI trial, in 2026 we plan to file our Pre-Marketing Approval (PMA) application for our Selective Cytopheretic Device (SCD) therapy as an organ-sparing and life-saving treatment for adult patients with Acute Kidney Injury (AKI) requiring continuous renal replacement therapy (CRRT)."

Industry Context

SeaStar Medical operates in the critical care and medical device sector, specifically targeting acute kidney injury (AKI) and hyperinflammation. The company's focus on a 'disease-modifying device' (SCD therapy) for conditions with no FDA-approved options positions it in a high-need, high-impact niche. The successful enrollment in pivotal trials and positive early commercial results for QUELIMMUNE suggest a potential shift in treatment paradigms for critically ill patients, aligning with broader industry trends towards innovative, targeted therapies for complex conditions. The DoD grant also highlights the growing interest in immunomodulation for trauma and burn injuries, expanding the potential market for SCD technology.

Comparison to Industry Standards

• The 75% survival rate for QUELIMMUNE in the SAVE Surveillance Registry for pediatric AKI patients with sepsis compares favorably to historical data, which previously indicated an approximate 50% reduction in loss of life compared to standard of care, as reported in Kidney Medicine. This suggests a significant improvement over existing treatment outcomes for this ultra-rare, life-threatening condition.
• The CMS agreement for the NEUTRALIZE-CRS trial is a rare award, with less than 100 clinical trials covered annually, indicating a high level of recognition and potential for future reimbursement pathways, which is a strong positive compared to typical clinical trial funding models.
• The adult AKI market opportunity, which the company is now prioritizing, is estimated to be 50 times larger than the U.S. pediatric AKI market, suggesting a strategic focus on a significantly larger addressable market compared to its initial commercial product.

Stakeholder Impact

• **Shareholders:** Experience significant dilution due to recent capital raises, but the capital raise extends the company's financial runway, reducing immediate liquidity concerns. Positive clinical and commercial progress could lead to future value creation.
• **Patients (Pediatric AKI):** Benefit from increased adoption of QUELIMMUNE therapy and positive survival data, offering a new treatment option for a life-threatening condition.
• **Patients (Adult AKI):** Potential future benefit from the NEUTRALIZE-AKI trial, which aims to provide an organ-sparing and life-saving treatment where no effective options currently exist.
• **Medical Centers/Hospitals:** New children's hospitals adopting QUELIMMUNE, and potential for CMS reimbursement for NEUTRALIZE-CRS trial expenses, indicating growing acceptance and financial support for the therapies.
• **Employees:** Cost-saving measures implemented, but focus on core development suggests job security for key personnel involved in SCD therapy development.

Next Steps

• Receive recommendations from the Data Safety Monitoring Review Board (DSMB) for the NEUTRALIZE-AKI interim analysis in Q3 2025.
• Present additional data from the SAVE Surveillance Registry.
• Onboard other notable children's hospitals to the QUELIMMUNE customer list.
• File Pre-Marketing Approval (PMA) application for SCD therapy for adult AKI in 2026, assuming successful NEUTRALIZE-AKI trial outcome.

Key Dates

Recommendation

SeaStar Medical has demonstrated significant operational progress with strong clinical trial enrollment, positive early commercial results for QUELIMMUNE, and a substantial capital raise that extends its financial runway. These factors reduce immediate liquidity risk and validate the company's technology. However, the company remains pre-profitability, relies heavily on the success of ongoing clinical trials, and has experienced considerable share dilution. While the long-term potential is promising, the inherent risks of clinical development and the need for future capital (despite the recent raise) suggest a 'hold' recommendation. Investors should monitor the upcoming interim trial results and further commercial adoption before making more aggressive investment decisions.

Keywords

Acute Kidney Injury, AKI, Sepsis, Selective Cytopheretic Device, SCD, QUELIMMUNE, NEUTRALIZE-AKI, Clinical Trial, Medical Device, Renal Replacement Therapy, CRRT, Hyperinflammation, Organ Failure, Biotechnology, Healthcare, FDA Approval, Nasdaq